Strategies for Combining Chemotherapy and Biotherapy in Melanoma

The L-Arginine-Nitric Oxide Pathway

1993 • 6,737 citations

Cancer statistics, 1999

1999 • 3,154 citations

Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.

1990 • 351 citations

Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b

1999 • 318 citations

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

1998 • 298 citations

Sequential chemoimmunotherapy in the treatment of metastatic melanoma.

1992 • 258 citations

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

1997 • 197 citations

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.

1993 • 181 citations

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-α

1996 • 176 citations

More Acid/Base Disturbances

1963 • 153 citations

Systemic treatments for advanced cutaneous melanoma.

1995 • 145 citations

Nitric oxide/nucleophile complexes inhibit the in vitro proliferation of A375 melanoma cells via nitric oxide release.

1993 • 137 citations

Augmentation of the human immune response by cyclophosphamide.

1982 • 136 citations

Enhancement of Dinitrochlorobenzene (DNCB) Contact Sensitization by Cyclophosphamide in the Guinea Pig**From the Department of Dermatology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104.

1967 • 133 citations

Combination of Chemotherapy With Interleukin-2 and Interferon Alfa for the Treatment of Metastatic Melanoma

1999 • 102 citations

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-α) and interleukin (IL-2) in patients with metastatic melanoma

1998 • 88 citations

Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum(II).

1980 • 79 citations

DEFECTIVE MONOCYTE KILLING IN PATIENTS WITH MALIGNANCIES AND RESTORATION OF FUNCTION DURING CHEMOTHERAPY

1980 • 72 citations

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen

1995 • 71 citations

Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-?-2a in patients with metastatic melanoma

1999 • 71 citations

Rationale for using TNFα and chemotherapy in regional therapy of melanoma

1994 • 55 citations

Enhancement of natural killer cytotoxicity by cis-diamminedichloroplatinum (II) in vivo and in vitro.

1986 • 55 citations

Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.

1994 • 46 citations

The anticancer drug, cisplatin, increases the naturally occurring cell-mediated lysis of tumor cells

1989 • 32 citations

Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells

1993 • 31 citations

Activation of human NK cells and monocytes with cisplatin in vitro

1990 • 31 citations

Enhanced susceptibility of cis‐diamminedichloroplatinum‐treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells

1993 • 27 citations

Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production

1992 • 22 citations

A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-?2a in patients with advanced malignant melanoma

1994 • 21 citations

Potentiation of adoptive immunotherapy by cis‐diamminedichloroplatinum(II), but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burden

1988 • 21 citations

Combination Effect of Recombinant Human Interleukin 1α with Antitumor Drugs on Syngeneic Tumors in Mice

1991 • 21 citations

Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.

1994 • 21 citations

Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha.

1991 • 21 citations

Effects of Platinum Antitumor Agents on <i>in vitro </i>Assays of Human Antitumor Immunity

1980 • 18 citations

Modulation by Cis-Diamminedichloroplatinum (II) of the Susceptibilities of Human T24 Lined and Freshly Separated Autologous Urinary Bladder Transitional Carcinoma Cells to Peripheral Blood Lymphocytes and Lymphokine Activated Killer Cells

1992 • 16 citations

Effect of cisplatin upon expression of in vivo immune tumor resistance

1993 • 14 citations

Synergistic antitumor activity of cisplatin and interleukin 1 in sensitive and resistant solid tumors.

1993 • 12 citations

Inhibition of DNA Repair and Sensitization of Cisplatin in Human Ovarian Carcinoma Cells by Interleukin-1α

1993 • 11 citations

Biologic agents as modifiers of chemotherapeutic effects

1991 • 11 citations

Interleukin 1 alpha and gamma-interferon induction of nitric oxide production from murine tumor-derived endothelial cells.

1996 • 10 citations

Abrogation of Suppressor Cells Activity by cis-Diamminedichloroplatinum (CDDP) Treatment Using Therapeutic Doses in Ovarian Cancer Patients

1994 • 9 citations

Dualistic effects of cis‐diammine‐dichloro‐platinum on the anti‐tumor efficacy of subsequently applied recombinant interleukin‐2 therapy: A tumor‐dependent phenomenon

1993 • 8 citations

Enhanced induction of lymphokine-activated killer activity following a single dose of cisplatin in cancer patients

1994 • 7 citations

Role of human blood monocytes in up-regulation of lymphokine (interleukin-2)-activated killer cell activity with cisplatin and FK-565.

1992 • 5 citations

Influence of schedule on the therapeutic efficacy of chemoimmunotherapy with doxorubicin and interleukin-2

1992 • 3 citations

Progress in Anti-Cancer Chemotherapy

1998 • 3 citations

Modulation of chemotherapy antineoplastic agents with biologic agents

1992 • 3 citations